625095-56-9

Upstream product

• 13422-80-5 3-(3-chlorophenyl)-3-oxopropanoic acid 
• 99-02-5 3'-Chloroacetophenone 
• 135505-20-3 (S)-(-)-methyl 3-(3-chlorophenyl)-3-hydroxypropanoate 

Downstream Products

• 625095-57-0 (S)-(-)-1-(3-Chlorophenyl)-1,3-propanediol 
• 693223-08-4 (4S)-(-)-trans-2-(4-nitrophenoxy)-2-oxo-4-(3-chlorophenyl)-1,3,2-dioxaphosphorinane 
• 625095-60-5 (+)-cis-9-{2-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-methyleneoxy]eth-1-yl}adenine 
• 693223-03-9 (+)-cis-5'-O-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphorinan-2-yl]cytosine-1-β-D-arabinofuranoside 
• 804561-62-4 2',3'-di-O-tert-butyldimethylsilyl-5'-O-cis-[4-(S)-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphoshorinan-2-yl]cytosine-1-β-D-arabinofuranoside 

Relevant academic research and scientific papers

NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES

Novel 2'-C-methyl nucleoside 5 '-monophosphate and 4'-C-methyl nucleoside 5'- monophosphate derivatives, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral inf

Novel 2'-C-methyl nucleoside derivatives

Compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described:

LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS

Methods for the synthesis of cyclic phosphonic acid diesters from 1,3-diols are described, whereby cyclic phosphonic acid diesters are produced by reacting a chiral 1,3-diol and an activated phosphonic acid in the presence of a Lewis acid.

Design, Synthesis, and Characterization of a Series of Cytochrome P 450 3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver

A new class of phosphate and phosphonate prodrugs, called HepDirect prodrugs, is described that combines properties of rapid liver cleavage with high plasma and tissue stability to achieve increased drug levels in the liver. The prodrugs are substituted c

Novel phosphonic acid based prodrugs of PMEA and its analogues

Prodrugs of Formula I, their uses, their intermediates, and their method of manufacture are described: 1wherein: M and V are cis to one another and MPO3H2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmet

Process for preparation of cyclic prodrugs of PMEA and PMPA

The method of preparing compounds of Formula I is described: wherein: M and V are cis to one another and MPO3H2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, and (R)-9-(2-phosphonylmethoxypropyl)adenine; wherein V is phenyl, optionally substituted with 1-2 substituents selected from a group consisting of fluoro, chloro, and bromo; comprising: coupling a chiral 1-phenylpropane-1,3-diol, wherein the phenyl may be optionally substituted, with MPOCl2 or an N-6 substituted analogue thereof. Additionally, methods and salt forms are described that enable isolation and purification of the desired isomer.